128 related articles for article (PubMed ID: 38270247)
21. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
22. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4.
Wong DVT; Ribeiro-Filho HV; Wanderley CWS; Leite CAVG; Lima JB; Assef ANB; Cajado AG; Batista GLP; González RH; Silva KO; Borges LPC; Alencar NMN; Wilke DV; Cunha TM; Figueira ACM; Cunha FQ; Lima-Júnior RCP
Cancer Chemother Pharmacol; 2019 Aug; 84(2):287-298. PubMed ID: 31011814
[TBL] [Abstract][Full Text] [Related]
23. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
[TBL] [Abstract][Full Text] [Related]
24. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
26. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
27. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling.
Iuchi K; Tasaki Y; Shirai S; Hisatomi H
Biomed Pharmacother; 2020 May; 125():109928. PubMed ID: 32004978
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
31. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
[TBL] [Abstract][Full Text] [Related]
32. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
33. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Canu B; Fioravanti A; Orlandi P; Di Desidero T; Alì G; Fontanini G; Di Paolo A; Del Tacca M; Danesi R; Bocci G
Neoplasia; 2011 Mar; 13(3):217-29. PubMed ID: 21390185
[TBL] [Abstract][Full Text] [Related]
35. NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer.
Baird L; Yamamoto M
Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33139492
[TBL] [Abstract][Full Text] [Related]
36. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
37. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
[TBL] [Abstract][Full Text] [Related]
38. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
39. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
40. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
